Combination of Lisaftoclax, Ixazomib, and Dexamethasone for Maintenance Therapy Following CAR-T in Patients with Transplant-Ineligible Relapsed/Refractory Ultra-High-Risk Multiple Myeloma: A Review of Two Cases and Relevant Literature - Summary - MDSpire
Advertisement
Combination of Lisaftoclax, Ixazomib, and Dexamethasone for Maintenance Therapy Following CAR-T in Patients with Transplant-Ineligible Relapsed/Refractory Ultra-High-Risk Multiple Myeloma: A Review of Two Cases and Relevant Literature
To evaluate the efficacy and safety of a combination therapy of ixazomib, lisaftoclax, and dexamethasone (ILD) as maintenance therapy following CAR-T in patients with relapsed/refractory ultra-high-risk multiple myeloma, highlighting its significance in the context of limited treatment options.
Key Findings:
Both patients achieved durable disease control and sustained MRD negativity after ILD therapy, with MRD negativity lasting for X months.
The ILD regimen was well-tolerated with manageable adverse events, including AEs such as Y and Z.
The combination therapy showed potential for optimizing MRD eradication in high-risk multiple myeloma, suggesting a new avenue for treatment.
Interpretation:
The ILD combination therapy may represent a promising maintenance treatment option for patients with limited choices following CAR-T therapy, particularly in those with ultra-high-risk characteristics, warranting further investigation into its broader applicability.
Limitations:
The study is based on only two case reports, limiting generalizability and potential biases in case selection.
Further formal evaluations and larger studies are needed to validate findings and assess long-term outcomes.
Conclusion:
The ILD regimen demonstrates potential efficacy and safety in maintaining MRD negativity in ultra-high-risk multiple myeloma patients post-CAR-T, warranting further investigation in larger cohorts.
